Departments of Gastroenterology, Universidade de São Paulo, São Paulo, SP, Brazil; Fundação Oncocentro de São Paulo (FOSP), São Paulo, SP, Brazil; Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP-HCFMUSP), São Paulo, SP, Brazil.
Departments of Gastroenterology, Universidade de São Paulo, São Paulo, SP, Brazil; Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (ICESP-HCFMUSP), São Paulo, SP, Brazil.
Clinics (Sao Paulo). 2023 Aug 26;78:100278. doi: 10.1016/j.clinsp.2023.100278. eCollection 2023.
Fecal Immunochemical Test (FIT) followed by a colonoscopy is an efficacious strategy to improve the adenoma detection rate and Colorectal Cancer (CRC). There is no organized national screening program for CRC in Brazil. The aim of this research was to describe the implementation of an organized screening program for CRC through FIT followed by colonoscopy, in an urban low-income community of São Paulo city. The endpoints of the study were: FIT participation rate, FIT positivity rate, colonoscopy compliance rate, Positive Predictive Values (PPV) for adenoma and CRC, and the rate of complications. From May 2016 to October 2019, asymptomatic individuals, 50-75 years old, received a free kit to perform the FIT. Positive FIT (≥ 50 ng/mL) individuals were referred to colonoscopy. 10,057 individuals returned the stool sample for analysis, of which (98.2%) 9,881 were valid. Women represented 64.8% of the participants. 55.3% of individuals did not complete elementary school. Positive FIT was 7.8% (776/9881). The colonoscopy compliance rate was 68.9% (535/776). There were no major colonoscopy complications. Adenoma were detected in 63.2% (332/525) of individuals. Advanced adenomatous lesions were found in 31.4% (165/525). CRC was diagnosed in 5.9% (31/525), characterized as adenocarcinoma: in situ in 3.2% (1/31), intramucosal in 29% (9/31), and invasive in 67.7% (21/31). Endoscopic treatment with curative intent for CRC was performed in 45.2% (14/31) of the cases. Therefore, in an urban low-income community, an organized CRC screening using FIT followed by colonoscopy ensued a high participation rate, and high predictive positive value for both, adenoma and CRC.
粪便免疫化学测试(FIT)后行结肠镜检查是提高腺瘤检出率和结直肠癌(CRC)的有效策略。巴西尚未建立有组织的 CRC 筛查计划。本研究旨在描述在圣保罗市一个城市低收入社区通过 FIT 后行结肠镜检查来开展有组织的 CRC 筛查计划。该研究的终点为:FIT 参与率、FIT 阳性率、结肠镜检查依从率、腺瘤和 CRC 的阳性预测值(PPV)以及并发症发生率。从 2016 年 5 月至 2019 年 10 月,50-75 岁的无症状个体收到了免费试剂盒以进行 FIT。FIT 阳性(≥50ng/mL)的个体被转介行结肠镜检查。共有 10057 人返回粪便样本进行分析,其中 9881 人(98.2%)的样本有效。参与者中女性占 64.8%。55.3%的个体未完成小学教育。FIT 阳性率为 7.8%(776/9881)。结肠镜检查依从率为 68.9%(535/776)。没有出现主要的结肠镜检查并发症。525 名个体中 63.2%(332/525)发现了腺瘤。高级腺瘤性病变占 31.4%(165/525)。CRC 的诊断率为 5.9%(31/525),表现为腺癌:原位癌占 3.2%(1/31),黏膜内癌占 29%(9/31),浸润性癌占 67.7%(21/31)。45.2%(14/31)的 CRC 病例行内镜下有治愈倾向的治疗。因此,在城市低收入社区,通过 FIT 后行结肠镜检查进行有组织的 CRC 筛查可获得较高的参与率,且对腺瘤和 CRC 均具有较高的阳性预测值。